Sifalimumab is a fully human monoclonal antibody targeting interferon-alpha. The levels of interferon-alpha are elevated in many patients with active systemic lupus erythematosus (SLE, or lupus) and other autoimmune disorders, and may be associated with disease activity. Sifalimumab may suppress the abnormal immune activity associated with lupus by binding to multiple interferon-alpha subtypes seen in the serum of lupus patients.
Fitur visualisasi ini dikembangkan menggunakan pendekatan Graph Theory untuk memetakan hubungan polifarmasi dan molekuler. Entitas (Obat, Target, Gen) direpresentasikan sebagai Simpul (Nodes), sedangkan hubungan biologisnya sebagai Sisi (Edges).
drugbank-id dan name pada skema XML DrugBank.targets/target yang memuat polipeptida sasaran.gene-name dan varian snp-effects.Tata letak grafik menggunakan algoritma Force-Directed Graph (Barnes-Hut). Model fisika ini menerapkan gaya tolak-menolak antar simpul (Gravitasi: -3000) agar tidak tumpang tindih, serta gaya pegas (Spring: 0.04) pada garis penghubung untuk fleksibilitas interaksi.
| Diethylstilbestrol | Diethylstilbestrol may increase the thrombogenic activities of Sifalimumab. |
| Chlorotrianisene | Chlorotrianisene may increase the thrombogenic activities of Sifalimumab. |
| Conjugated estrogens | Conjugated estrogens may increase the thrombogenic activities of Sifalimumab. |
| Estrone | Estrone may increase the thrombogenic activities of Sifalimumab. |
| Estradiol | Estradiol may increase the thrombogenic activities of Sifalimumab. |
| Dienestrol | Dienestrol may increase the thrombogenic activities of Sifalimumab. |
| Ethinylestradiol | Ethinylestradiol may increase the thrombogenic activities of Sifalimumab. |
| Mestranol | Mestranol may increase the thrombogenic activities of Sifalimumab. |
| Estriol | Estriol may increase the thrombogenic activities of Sifalimumab. |
| Estrone sulfate | Estrone sulfate may increase the thrombogenic activities of Sifalimumab. |
| Quinestrol | Quinestrol may increase the thrombogenic activities of Sifalimumab. |
| Hexestrol | Hexestrol may increase the thrombogenic activities of Sifalimumab. |
| Tibolone | Tibolone may increase the thrombogenic activities of Sifalimumab. |
| Synthetic Conjugated Estrogens, A | Synthetic Conjugated Estrogens, A may increase the thrombogenic activities of Sifalimumab. |
| Synthetic Conjugated Estrogens, B | Synthetic Conjugated Estrogens, B may increase the thrombogenic activities of Sifalimumab. |
| Polyestradiol phosphate | Polyestradiol phosphate may increase the thrombogenic activities of Sifalimumab. |
| Esterified estrogens | Esterified estrogens may increase the thrombogenic activities of Sifalimumab. |
| Zeranol | Zeranol may increase the thrombogenic activities of Sifalimumab. |
| Equol | Equol may increase the thrombogenic activities of Sifalimumab. |
| Promestriene | Promestriene may increase the thrombogenic activities of Sifalimumab. |
| Methallenestril | Methallenestril may increase the thrombogenic activities of Sifalimumab. |
| Epimestrol | Epimestrol may increase the thrombogenic activities of Sifalimumab. |
| Moxestrol | Moxestrol may increase the thrombogenic activities of Sifalimumab. |
| Estradiol acetate | Estradiol acetate may increase the thrombogenic activities of Sifalimumab. |
| Estradiol benzoate | Estradiol benzoate may increase the thrombogenic activities of Sifalimumab. |
| Estradiol cypionate | Estradiol cypionate may increase the thrombogenic activities of Sifalimumab. |
| Estradiol valerate | Estradiol valerate may increase the thrombogenic activities of Sifalimumab. |
| Biochanin A | Biochanin A may increase the thrombogenic activities of Sifalimumab. |
| Formononetin | Formononetin may increase the thrombogenic activities of Sifalimumab. |
| Estetrol | Estetrol may increase the thrombogenic activities of Sifalimumab. |
| Cetuximab | The risk or severity of adverse effects can be increased when Cetuximab is combined with Sifalimumab. |
| Human immunoglobulin G | The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Sifalimumab. |
| Omalizumab | The risk or severity of adverse effects can be increased when Omalizumab is combined with Sifalimumab. |
| Adalimumab | The risk or severity of adverse effects can be increased when Adalimumab is combined with Sifalimumab. |
| Abciximab | The risk or severity of adverse effects can be increased when Abciximab is combined with Sifalimumab. |
| Gemtuzumab ozogamicin | The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Sifalimumab. |
| Indium In-111 satumomab pendetide | The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Sifalimumab. |
| Infliximab | The risk or severity of adverse effects can be increased when Infliximab is combined with Sifalimumab. |
| Trastuzumab | The risk or severity of adverse effects can be increased when Trastuzumab is combined with Sifalimumab. |
| Rituximab | The risk or severity of adverse effects can be increased when Rituximab is combined with Sifalimumab. |
| Basiliximab | The risk or severity of adverse effects can be increased when Basiliximab is combined with Sifalimumab. |
| Muromonab | The risk or severity of adverse effects can be increased when Muromonab is combined with Sifalimumab. |
| Digoxin Immune Fab (Ovine) | The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Sifalimumab. |
| Ibritumomab tiuxetan | The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Sifalimumab. |
| Tositumomab | The risk or severity of adverse effects can be increased when Tositumomab is combined with Sifalimumab. |
| Alemtuzumab | The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Sifalimumab. |
| Capromab pendetide | The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Sifalimumab. |
| Efalizumab | The risk or severity of adverse effects can be increased when Efalizumab is combined with Sifalimumab. |
| Antithymocyte immunoglobulin (rabbit) | The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Sifalimumab. |
| Natalizumab | The risk or severity of adverse effects can be increased when Natalizumab is combined with Sifalimumab. |
| Palivizumab | The risk or severity of adverse effects can be increased when Palivizumab is combined with Sifalimumab. |
| Daclizumab | The risk or severity of adverse effects can be increased when Daclizumab is combined with Sifalimumab. |
| Bevacizumab | The risk or severity of adverse effects can be increased when Bevacizumab is combined with Sifalimumab. |
| Technetium Tc-99m arcitumomab | The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Sifalimumab. |
| Eculizumab | The risk or severity of adverse effects can be increased when Eculizumab is combined with Sifalimumab. |
| Panitumumab | The risk or severity of adverse effects can be increased when Panitumumab is combined with Sifalimumab. |
| Ranibizumab | The risk or severity of adverse effects can be increased when Ranibizumab is combined with Sifalimumab. |
| Galiximab | The risk or severity of adverse effects can be increased when Galiximab is combined with Sifalimumab. |
| Pexelizumab | The risk or severity of adverse effects can be increased when Pexelizumab is combined with Sifalimumab. |
| Afelimomab | The risk or severity of adverse effects can be increased when Afelimomab is combined with Sifalimumab. |
| Epratuzumab | The risk or severity of adverse effects can be increased when Epratuzumab is combined with Sifalimumab. |
| Bectumomab | The risk or severity of adverse effects can be increased when Bectumomab is combined with Sifalimumab. |
| Oregovomab | The risk or severity of adverse effects can be increased when Oregovomab is combined with Sifalimumab. |
| IGN311 | The risk or severity of adverse effects can be increased when IGN311 is combined with Sifalimumab. |
| Adecatumumab | The risk or severity of adverse effects can be increased when Adecatumumab is combined with Sifalimumab. |
| Labetuzumab | The risk or severity of adverse effects can be increased when Labetuzumab is combined with Sifalimumab. |
| Matuzumab | The risk or severity of adverse effects can be increased when Matuzumab is combined with Sifalimumab. |
| Fontolizumab | The risk or severity of adverse effects can be increased when Fontolizumab is combined with Sifalimumab. |
| Bavituximab | The risk or severity of adverse effects can be increased when Bavituximab is combined with Sifalimumab. |
| CR002 | The risk or severity of adverse effects can be increased when CR002 is combined with Sifalimumab. |
| Rozrolimupab | The risk or severity of adverse effects can be increased when Rozrolimupab is combined with Sifalimumab. |
| Girentuximab | The risk or severity of adverse effects can be increased when Girentuximab is combined with Sifalimumab. |
| Obiltoxaximab | The risk or severity of adverse effects can be increased when Obiltoxaximab is combined with Sifalimumab. |
| XTL-001 | The risk or severity of adverse effects can be increased when XTL-001 is combined with Sifalimumab. |
| NAV 1800 | The risk or severity of adverse effects can be increased when NAV 1800 is combined with Sifalimumab. |
| Briakinumab | The risk or severity of adverse effects can be increased when Briakinumab is combined with Sifalimumab. |
| Otelixizumab | The risk or severity of adverse effects can be increased when Otelixizumab is combined with Sifalimumab. |
| AMG 108 | The risk or severity of adverse effects can be increased when AMG 108 is combined with Sifalimumab. |
| Iratumumab | The risk or severity of adverse effects can be increased when Iratumumab is combined with Sifalimumab. |
| Enokizumab | The risk or severity of adverse effects can be increased when Enokizumab is combined with Sifalimumab. |
| Ramucirumab | The risk or severity of adverse effects can be increased when Ramucirumab is combined with Sifalimumab. |
| Farletuzumab | The risk or severity of adverse effects can be increased when Farletuzumab is combined with Sifalimumab. |
| Veltuzumab | The risk or severity of adverse effects can be increased when Veltuzumab is combined with Sifalimumab. |
| Ustekinumab | The risk or severity of adverse effects can be increased when Ustekinumab is combined with Sifalimumab. |
| Trastuzumab emtansine | The risk or severity of adverse effects can be increased when Trastuzumab emtansine is combined with Sifalimumab. |
| PRO-542 | The risk or severity of adverse effects can be increased when PRO-542 is combined with Sifalimumab. |
| TNX-901 | The risk or severity of adverse effects can be increased when TNX-901 is combined with Sifalimumab. |
| Inotuzumab ozogamicin | The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with Sifalimumab. |
| RI 624 | The risk or severity of adverse effects can be increased when RI 624 is combined with Sifalimumab. |
| Stamulumab | The risk or severity of adverse effects can be increased when MYO-029 is combined with Sifalimumab. |
| CT-011 | The risk or severity of adverse effects can be increased when CT-011 is combined with Sifalimumab. |
| Leronlimab | The risk or severity of adverse effects can be increased when Leronlimab is combined with Sifalimumab. |
| Glembatumumab vedotin | The risk or severity of adverse effects can be increased when Glembatumumab vedotin is combined with Sifalimumab. |
| Olaratumab | The risk or severity of adverse effects can be increased when Olaratumab is combined with Sifalimumab. |
| IPH 2101 | The risk or severity of adverse effects can be increased when IPH 2101 is combined with Sifalimumab. |
| TB-402 | The risk or severity of adverse effects can be increased when TB-402 is combined with Sifalimumab. |
| Caplacizumab | The risk or severity of adverse effects can be increased when Caplacizumab is combined with Sifalimumab. |
| IMC-1C11 | The risk or severity of adverse effects can be increased when IMC-1C11 is combined with Sifalimumab. |
| Eldelumab | The risk or severity of adverse effects can be increased when Eldelumab is combined with Sifalimumab. |
| Lumiliximab | The risk or severity of adverse effects can be increased when Lumiliximab is combined with Sifalimumab. |